American Century Companies Inc. Raises Holdings in Genmab A/S Sponsored ADR $GMAB

Key Points

• American Century Companies Inc. increased its holdings in Genmab A/S by 19.8% in the first quarter, owning approximately 0.06% of the company, valued at $7.52 million.
• Genmab A/S reported earnings per share of $0.54 for the latest quarter, exceeding analyst expectations of $0.39, along with a revenue of $925 million.
• Numerous analysts have adjusted their price targets for Genmab A/S, with the consensus target price now at $37.60 and an average rating of "Moderate Buy."

American Century Companies Inc. boosted its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 19.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 383,891 shares of the company's stock after buying an additional 63,316 shares during the period. American Century Companies Inc. owned approximately 0.06% of Genmab A/S worth $7,517,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Genmab A/S in the 4th quarter valued at approximately $2,463,000. GAMMA Investing LLC lifted its stake in shares of Genmab A/S by 1,465.3% in the 1st quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock valued at $656,000 after purchasing an additional 31,343 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Genmab A/S by 18.8% in the 4th quarter. Northern Trust Corp now owns 599,381 shares of the company's stock valued at $12,509,000 after purchasing an additional 94,858 shares during the last quarter. Fifth Third Bancorp lifted its stake in shares of Genmab A/S by 16.6% in the 1st quarter. Fifth Third Bancorp now owns 42,151 shares of the company's stock valued at $825,000 after purchasing an additional 6,015 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Genmab A/S by 1.7% in the 1st quarter. Envestnet Asset Management Inc. now owns 736,326 shares of the company's stock valued at $14,417,000 after purchasing an additional 12,545 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Stock Performance

NASDAQ GMAB traded down $0.24 on Monday, reaching $24.87. 676,680 shares of the stock traded hands, compared to its average volume of 1,316,170. The company has a fifty day moving average price of $22.22 and a 200-day moving average price of $21.28. The company has a market cap of $15.96 billion, a price-to-earnings ratio of 12.50, a PEG ratio of 7.22 and a beta of 0.93. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $27.93.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GMAB. Truist Financial raised their price objective on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. Zacks Research lowered Genmab A/S from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. HC Wainwright raised their price target on Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Friday, August 15th. Finally, Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Genmab A/S has a consensus rating of "Moderate Buy" and a consensus price target of $37.60.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.